Scott Rocklage Efforts in Finding Cure for the DM1 condition

Scott Rocklage of 5AM Ventures and several other partners such as Sanofi Ventures, Kleiner Perkins, RA Capital Management, Novartis Venture Fund, and Alexandria Venture Investments, have been lead financiers to Expansion Therapeutics, in the fight of genetic disorders. One of such a disease is Myotonic dystrophy type I (DM1), which is the main cause of adults’ muscular dystrophy. The problem is the disease’s symptoms do not present themselves until the RNA has reached toxic levels, and it’s at this point the DM1 condition occurs.

The manifestation of the DM1 condition, the heart, hormonal system, muscles, gastrointestinal system, respiratory system, and the central nervous system starts to become defective. This condition is capable of affecting the whole family as it gets worse with every subsequent generation. The medical community is yet to get DM1’s effective treatment.

RNAs are molecules transferred from DNA and changed into proteins. Expansion Therapeutics do make medications which confront the RNA in RNA driven diseases. Their major concern, however, is the expansion repeat disorders, which are hereditary illnesses, that fail to adequately respond to the current medication. Such illnesses happen to have defective genes caused by replication of tiny portions of DNA, DM1 is an example of such illnesses.

In a press release issued by Scott Rocklage, he stated that Expansion Therapeutics have their researches are done in Matthew D. Disney, Ph.D.’s laboratories, which they use as the foundation of their research on this condition, led by Mr. Disney himself, as the chief scientific researcher.

Other than Mr. Rocklage working together with the Expansion Therapeutics in the research team, there are other goals they have achieved together. In fact, they are planning on how to advance the small molecule medicines’ field that targets RNA, with the aim of creating medications for those patients with no options.

Rocklage holds a bachelors degree in Chemistry from California University. He is also a holder of a Ph.D. in Chemistry from Massachusetts Institute of Technology. Rocklage started working at 5AM Ventures in 2003, and in 2004 he was made the Managing Partner, a position he holds to date.

He has been in healthcare management for over 30 years. He is an inventor of several medications. Rocklage has been appointed for leadership roles in several boards and organizations such as Cubist Pharmaceuticals where he is the CEO, Relypsa, Achaegon and Novira’s board chair, and many other roles.


Connect with Dr. Scott Rocklage on LinkedIn.

Malcolm CasSelle and what he does

Worldwide Asset eXchange is known as WAX, a decentralized network used for buying and selling in-game items. Its great because WAX will decrease the transaction costs that weren’t available before. The platform is made so that players can exchange items and creates a tokenization. This allows the buyer to keep ownership of their item. The end goal is to have physical assets they can use in the future. There is a big challenge, the system has to make sure that tokens on the block chain are connected to their respective assess. There are also other elements in WAX’s design that try to compensate for this.

To constantly make transactions, token holders need to regulate their transactions to authorize future actions. The exchange process is done with transfer agents that calculate ratings, supervise guilds and regulate the proof of stake algorithm. When transfer agents don’t do their job, the guild rating is effected and they are given less influence. Eventually if the agents don’t do their job, they won’t be re-elected to get their position. Its a really crazy concept and its something that can’t be done with physical assets. There’s no way you would be able to sell half of a DeLorean.

Malcolm CasSelle is an investor who attended Stanford University and is part of the Massachusetts Institution of Technology Alumni network. He is also a President, mentor, advisory, and founder of PCCW. He has also stressed the importance of bitcoin and the massive potential it has if people are will to dig into it.

He is most well known for founding the Worldwide Asset eXchange or WAX. WAX has created a new trading environment for people who play games and want to make sure that their items are traded properly. The system has a lot of potential for how future assets should be handled.


Scott Rocklage holds a prominent position as the managing partner at 5AM Ventures capital firm. This firm mainly deals with start-up investments, spinouts, early-stage, seed and growth capital. 5AM Ventures has a key focus towards making investments in medical technology, biotechnology, product discovery platforms and biopharmaceuticals. All those companies that show growth and strive to discover and develop drugs are given the highest priority by the capital firm. This is especially if these companies are more interested in therapeutic areas such as diabetes, metabolic diseases, anti-infectives and oncology (the scientific study of prevention, diagnosis, and treatment of cancer). Medical technology is an area of focus for 5AM ventures as it shows interest in materials science, imaging agents, diagnostics, drug delivery and medical devices.

Initially, Dr. Scott was just a venture partner at the firm in 2003. His position was elevated to managing partner in 2004 attributing to his impressive expertise in healthcare management and related fields. In his position, the doctor has been successful to enter a number of multiple drug candidates into clinical trials and has also led to FDA approving the three U.S. New Drug Application (Teslascan, Cubicin and Omniscan)Having been the president and the chief executive officer of Nycomed Salutar has given him a lot of experience in this field. To add on to this, he has served as the chief executive officer and chairman of Cubist Pharmaceuticals as well as holding various positions at Salutar and Catalytica.

Dr. Scott chairs the boards of Epirus (NASDAQ: EPRS) and Pulmatrix (NASDAQ: PULM). At the moment he is also a Board chairman of Kinestral, Rennovia, and Cidara (NASDAQ: CDTX). In the past, Dr. Scott was a Chairman of Relypsa (NASDAQ: CDTX) and Novira (acquired by Johnson and Johnson). To add more to his resume, Dr. Rocklage has previously been the Executive Chairman of Miikana (acquired by EntreMed), Ilypsa (acquired by Amgen) and Semprus (acquired by Teleflex). When he comes to his education, this successful doctor earned his Ph.D. in chemistry from the Massachusetts Institute of Technology (MIT). Here, the doctor left after conducting research activities in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005).


To learn more, visit